MedPath

Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography

Not Applicable
Active, not recruiting
Conditions
Coronary Artery Disease
Interventions
Radiation: CT Coronary Angiography (CTCA)
Registration Number
NCT03952351
Lead Sponsor
University of Edinburgh
Brief Summary

Most patients presenting to hospital with symptoms of a heart attack are sent home without further tests once a heart attack has been ruled out. Current strategies to assess patients with a suspected heart attack involve blood tests to measure troponin, a protein released into the bloodstream when the heart muscle is damaged.

Despite having had a heart attack ruled-out, some patients have unrecognised heart disease and are at risk of having a heart attack in the future. However, clinicians do not know what is the best approach to identify and treat these patients.

This study will use a heart scan known as computed tomography coronary angiogram (CTCA) to look for unrecognised heart disease in patients who have had a heart attack ruled out. In an earlier study, the Investigators performed this scan in patients referred to the outpatient cardiology clinic with stable chest pain and found that this improved the diagnosis of heart disease, leading to improvement in patient care that prevented future heart attacks.

Previous research from the Investigators has also found that troponin levels below those used to diagnose a heart attack may help to identify those who are at greater risk of having a heart attack in the future.

The aim of this study is to find out if patients with these low levels of troponin, where a heart attack has been ruled out, will benefit from CTCA to look for unrecognised coronary heart disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
3170
Inclusion Criteria
  • Presenting to hospital with symptoms of suspected acute coronary syndrome
  • Age 18 years and over
  • Maximum high-sensitivity cardiac troponin concentration between 5ng/L and the 99th percentile
Exclusion Criteria
  • Diagnosis of myocardial infarction during index presentation
  • Clear alternative diagnosis or participant requires further inpatient clinical assessment
  • Recent CTCA or invasive coronary angiogram (within 1 year)
  • Patient inability to undergo CT scanning, e.g. due to severe renal failure (estimated glomerular filtration rate <30 mL/min) or major allergy to iodinated contrast media
  • Current pregnancy or breast feeding
  • Inability to give informed consent
  • Further investigation for coronary artery disease would not be in the patient's interest, e.g. due to limited life expectancy, quality of life or functional status
  • Previous randomisation into the trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CTCA with standard careCT Coronary Angiography (CTCA)Patients will be referred for CT Coronary Angiography, ideally within 2 weeks of randomisation
Primary Outcome Measures
NameTimeMethod
Composite of myocardial infarction or cardiac deathRandomisation through to study completion, median duration of 36 months

The first event of myocardial infarction or cardiac death

Secondary Outcome Measures
NameTimeMethod
Myocardial InfarctionRandomisation through to study completion, median duration of 36 months

The first event of myocardial infarction (MI). MI will be defined according to the 4th Universal Definition of Myocardial Infarction

Quality of life as assessed by the EQ-5D-5L3, 12 and 24 months
Symptomatic status as assessed by the short form Seattle Angina Questionnaire (SAQ-7)3, 12 and 24 months
Cardiac deathRandomisation through to study completion, median duration of 36 months

Cardiac death will be defined as death resulting from an acute myocardial infarction, sudden cardiac death, or death due to heart failure.

All-cause deathRandomisation through to study completion, median duration of 36 months
Unscheduled urgent coronary revascularisationRandomisation through to study completion, median duration of 36 months

Unscheduled urgent coronary revascularisation will be identified via record linkage from central NHS registers (e.g. the Scottish Morbidity Register by the Information Services Division (ISD) Scotland) or from extracts obtained from the participating hospitals electronic patient record system.

Cardiovascular deathRandomisation through to study completion, median duration of 36 months

Cardiovascular death will be defined as death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular haemorrhage, and death due to other cardiovascular causes

Non-cardiovascular deathRandomisation through to study completion, median duration of 36 months
Hospital reattendance with suspected ACSRandomisation through to study completion, median duration of 36 months

Reattendance with suspected ACS will be defined as any unscheduled hospital attendance where cardiac troponin testing is performed for suspected ACS following randomisation

Proportion of patients with major bleeding (BARC 3-5)Randomisation through to study completion, median duration of 36 months

Bleeding will be defined according to the Bleeding Academic Research Consortium (BARC) definition of bleeding. We will use pre-defined codes from International Classification of Diseases (ICD-10) and Office of Population Censuses and Surveys (OPCS) to classify each bleeding event as per the BARC definition.

Trial Locations

Locations (9)

NHS Lothian

🇬🇧

Edinburgh, United Kingdom

Milton Keynes University NHS Hospital

🇬🇧

Milton Keynes, United Kingdom

University Hospitals Plymouth NHS Trust

🇬🇧

Plymouth, United Kingdom

NHS Greater Glasgow and Clyde

🇬🇧

Glasgow, United Kingdom

Lewisham & Greenwich NHS Trust

🇬🇧

London, United Kingdom

North Tees NHS Hospital Foundation

🇬🇧

Stockton, United Kingdom

University Hospital Southampton NHS Trust

🇬🇧

Southampton, United Kingdom

Torbay & South Devon NHS Foundation Trust

🇬🇧

Torquay, United Kingdom

Royal Berkshire NHS Foundation Trust

🇬🇧

Reading, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath